TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25

Benzinga Newsdesk www.benzinga.com Negative 66.4%

Neg 66.4% Neu 0% Pos 0%

TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $1.5 to $1.25.